Skip to main content

Table 2 Clinical and disease information

From: Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy

  N = 683
AR duration (years), mean ± SD 10.8 ± 8.8
Etiologic allergen, N (%)
 Dust mite 199 (30.0)
 Pollen 325 (48.9)
 Dust mite and pollen 140 (21.1)
Type of AR, N (%)
 Intermittent 200 (29.4)
 Persistent 480 (70.6)
ARIA Severity of AR, N (%)
 Mild 92 (13.5)
 Moderate/severe 591 (86.5)
VALERO severity of AR, N (%)
 Mild 92 (13.5)
 Moderate 380 (55.6)
 Severe 211 (30.9)
Current pharmacological treatment, N (%)
 No 197 (28.8)
 Yes 486 (71.2)
Current allergen immunotherapy, N (%)
 No 159 (23.8)
 Yes 508 (76.2)
  SCIT 304 (60.7)
  SLIT 194 (38.7)
  Both 3 (0.6)
Time from current AIT initiation (months), mean ± SD 12.8 ± 14.2
Current use of medication versus before AIT initiation, N (%)
 More medication 10 (1.9)
 The same medication 112 (20.7)
 Less medication 418 (77.4)
Current level of symptoms versus before AIT initiation, N (%)
 More symptoms 10 (1.9)
 The same level of symptoms 92 (17.1)
 Less symptoms 437 (81.1)
  1. AIT allergen immunotherapy, AR allergy rhinitis, SCIT subcutaneous immunotherapy, SD standard deviation, SLIT sublingual immunotherapy